The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance
Microbial Genomics · 20.03.2025 · 11 (3)
DOI: 10.1099/mgen.0.001375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Genomics, erschienen am 20.03.2025. Verfasst von Daniel Bugembe Lule und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Hauptthemen laut MEDLINE: HIV-1, Drug Resistance, Viral, HIV Infections, Nanopore Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Health, Medical Research Council.
Abstract (Originalsprache)
HIV continues to be a significant global public health concern. In 2022, an estimated 29.8 million people living with HIV received antiretroviral treatment (ART). From this, an estimated 10–15% of individuals living with HIV have drug-resistant strains of the virus. Testing for resistance to antiretroviral drugs is recommended before initiating ART. However, such services are often inaccessible due to costs and the need for complex laboratory infrastructure. The assessment of HIV drug resistance (HIVDR) relies on genotyping sequencing and algorithms to interpret genotypic resistance test results. Genotypic assays involve Sanger sequencing of the reverse transcriptase ( RT ), protease ( PR ) and integrase ( IN ) genes of circulating RNA in plasma to detect mutations that are known to confer drug resistance. While state-of-the-art sequencing technologies have swept the globe and enhanced our global pandemic response capabilities, they are still sparingly used for HIVDR surveillance. The scale-up of ART, especially in low- and middle-income countries, necessitates the establishment of cheap, expeditious and decentralized methods for HIVDR monitoring. Here, we outline how one low-capital next-generation sequencing platform, namely, nanopore sequencing, could augment efforts in expanding HIVDR surveillance efforts, especially in resource-limited settings. We discuss that because of its versatility, nanopore sequencing can accelerate HIVDR surveillance in conjunction with scaling up ART efforts and outline some of the challenges that need to be considered before its widespread and routine adaptation to detect drug resistance rapidly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
- Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Unit, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.
- St. Georges University of London, Cranmer Terrace, Tooting, London SW17 0RE, UK.
- Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.
- Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Förderung
- NIAID NIH HHS
- National Institute of Health
- Medical Research Council
Zitieren
APA
Lule, D. B., Ssemwanga, D., Kaleebu, P., & Tully, D. C. (2025). The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance. Microbial Genomics, 11(3). https://doi.org/10.1099/mgen.0.001375
Vancouver
Lule DB, Ssemwanga D, Kaleebu P, Tully DC. The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance. Microbial Genomics. 2025;11(3). doi:10.1099/mgen.0.001375
BibTeX
@article{Lule2025,
author = {Lule, Daniel Bugembe and Ssemwanga, Deogratius and Kaleebu, Pontiano and Tully, Damien C},
title = {The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance},
journal = {Microbial Genomics},
year = {2025},
volume = {11},
number = {3},
doi = {10.1099/mgen.0.001375}
}
EUVIMED